Streptokinase vs Urokinase: Mechanism, Process, and Selection Compared
Published on November 4, 2026

figure1. Overview comparing the streptokinase and urokinase thrombolysis pathways
Classification:Enzymology & Enzyme Engineering (associated: Biocatalysis & Biotransformation; Protein Purification & Chromatography)
1. Applications First: The Shared Mission of Two Thrombolytic Routes
1.1 The Two Enzymes Do the Same Job
Start with an everyday analogy. A blood vessel is like a delivery pipe, and a thrombus is a blockage that chokes the flow. The body's scavenger, plasmin, exists as inactive plasminogen and needs a starter to wake it. Streptokinase and urokinase are two different designs of that starter.
Their shared mission is highly consistent: convert plasminogen into plasmin so that plasmin degrades the fibrin in a clot and reopens the blocked vessel. Because the goal is the same, they are often placed side by side on the same selection table.
In clinical practice, the core of thrombolysis is to recanalize as early as possible within the appropriate time window, and enzyme activity, selectivity, and safety directly affect the speed of recanalization and bleeding risk. This is exactly why the two are compared.
1.2 Application Scenarios: From Acute Myocardial Infarction to Catheter Recanalization
Both are used mainly for thrombotic emergencies and iatrogenic thrombosis. Acute myocardial infarction, pulmonary embolism, deep-vein thrombosis, and peripheral arterial occlusion all rely on thrombolytics for rapid recanalization; urokinase is also used to clear venous lines and central-line thrombi.
• Acute myocardial infarction: quickly reopen the infarct-related vessel to salvage myocardium
• Pulmonary embolism: relieve pulmonary circulation obstruction and improve gas exchange
• Deep-vein thrombosis and peripheral arterial occlusion: restore distal blood flow
• Venous line or central-line recanalization: clear thrombus inside the catheter
The difference here: streptokinase is usually used in one-time acute thrombolysis, while urokinase, with lower immunogenicity and repeat dosing, suits scenarios needing repeated treatment or long-term catheter management.
2. Mechanism: A Borrowed Key versus a Self-Made Blade
2.1 Streptokinase: Borrowing Plasminogen to Form an Active Complex
Streptokinase is not a protease; it is more like a borrowed key. It first binds human plasminogen to form a 1:1 SK-plasminogen complex, which then gains protease activity and cleaves more free plasminogen into plasmin. The key cleavage site is the Arg561-Val562 peptide bond of plasminogen.
This process can be broken into three steps:
• Step 1: streptokinase binds plasminogen to form a 1:1 complex
• Step 2: the complex changes conformation and gains protease activity
• Step 3: the activated complex cleaves more plasminogen into plasmin
Put plainly, streptokinase does not cut itself but borrows plasminogen's body to make a working tool. This keeps it cost-effective, but being a foreign protein also brings immunogenicity.
2.2 Urokinase: A Human Protease from Single Chain to Two Chain
Urokinase (uPA) is a human serine protease of about 411 amino acids with three domains, each with a distinct role.
• EGF-like domain: binds the urokinase receptor (uPAR) on the cell surface for precise localization
• Kringle domain: participates in protein-protein interactions and stabilizes the conformation
• Serine protease catalytic domain: cuts the substrate and is the true blade
It exists first as a low-activity single-chain precursor (pro-UK) and becomes far more active after cleavage into a two-chain form (HMW-uPA). It can also use the urokinase receptor (uPAR) to localize plasmin generation, participating in tissue remodeling and cell behavior, which is why it is widely used as a tool enzyme in cell biology and cancer research.
It can also use the urokinase receptor (uPAR) to localize plasmin generation, participating in tissue remodeling and cell behavior, which is why it is widely used as a tool enzyme in cell biology and cancer research.
2.3 The Shared Endpoint: Turning Plasminogen into Plasmin
Despite different mechanisms, both converge on the same endpoint: activate plasminogen into plasmin, and plasmin degrades fibrin. Understanding this convergence clarifies why they can substitute for each other, and why the choice depends more on safety, cost, and scenario than on activity level.
In terms of identity, streptokinase is a foreign protein and requires allergy-history assessment before use; urokinase is an endogenous protein and causes fewer immune reactions. This difference directly determines their selection positioning.

figure2. Comparison of the streptokinase and urokinase activation mechanisms
3. Technical Route and Source Comparison: Why One Is Cheap and the Other More Human
3.1 Source: Streptococci versus Urine, Cell Culture, or Recombinant
Streptokinase comes from beta-hemolytic streptococci, traditionally via streptococcal fermentation and now often by recombinant expression; urokinase was first extracted from human urine, then moved to kidney-cell culture and recombinant expression, such as in E. coli, CHO, or yeast. Source directly determines human derivation, immunogenicity, and price.
In short, streptokinase is cheap but picky; urokinase is human-derived but costlier.
3.2 Production and Purification Paths
Both face host selection and expression strategy upstream. Streptokinase in E. coli often forms inclusion bodies requiring refolding, or is secreted via yeast; urokinase must balance E. coli refolding, CHO human-like modifications, and yeast glycosylation differences. Downstream, both can use affinity chromatography, such as Ni-NTA or benzamidine affinity resin, combined with ion exchange and size exclusion.
For urokinase from human or animal-derived culture, virus inactivation and removal are key to safety, often via low-pH, heat, and nanofiltration.
3.3 Immunogenicity and Fibrin Selectivity Trade-offs
Streptokinase is a foreign antigen, prone to antibodies and allergy, with limited repeat use; urokinase is more human, less immunogenic, and repeatably dosed. But both are non-fibrin-selective, causing systemic fibrinolysis and raising bleeding risk, especially intracranial. For higher fibrin selectivity, tPA is considered, but at notably higher cost.
Comparing the three side by side makes the differences clearer:
• Streptokinase: cheap, highly immunogenic, non-fibrin-selective, one-time use
• Urokinase: human-derived, low immunogenicity, repeatably dosed, non-fibrin-selective
• tPA: higher fibrin selectivity, relatively lower bleeding risk, notably higher cost
4. Process Control and Quality Control Points
4.1 Activity Assay and Single- to Two-Chain Ratio
Activity measurement is affected by whether it is fibrin-dependent; different methods, such as the European Pharmacopoeia chromogenic assay, may assess potency inconsistently. For urokinase, the single- to two-chain ratio significantly affects activity, so it must be included in QC.
4.2 Purity, Endotoxin, and Impurity Control
Final product controls include specific activity, purity, endotoxin, residual host protein and DNA, and sterility. For in vivo or repeat dosing, impurity control matters most; for in vitro research, activity and batch-to-batch reproducibility are key.
• Specific activity (U/mg) and purity (e.g., HPLC, SDS-PAGE)
• Endotoxin (LAL) and residual host protein, DNA
• Sterility and the single- to two-chain ratio (for urokinase)
• Stability and batch-to-batch consistency
4.3 Stability and Batch Consistency
One evaluates activity loss during storage and transport of lyophilized or liquid formats, where buffer, pH, and stabilizers determine shelf life. Batch-to-batch activity consistency and within-batch uniformity are QC priorities and a basis for buyers to judge reliable supply.
5. Selection: How R&D and Procurement Choose Between the Two
5.1 Judge by Application Scenario
For one-time, budget-sensitive acute thrombolysis, streptokinase is often cost-effective; for repeated reactions or venous-line and catheter recanalization, urokinase fits better.
5.2 Judge by Safety and Repeat Use
If immunogenicity matters and repeat dosing is needed, choose urokinase; if assessing bleeding risk, both require facing the non-fibrin-selective limitation, with anticoagulation management and contraindication assessment. For patients needing long-term anticoagulation or with recent surgery, thrombolysis is usually more cautious and must weigh benefit against risk.
5.3 Judge by Cost and Supply
The decision can be filtered quickly by a few points:
• Source and specific activity: source affects immunogenicity and safety, while specific activity reflects thrombolytic potency
• Impurities and stability: endotoxin, host residue, single- to two-chain ratio, and batch consistency
• Use and scale: benchtop values consistency, pilot values scale-up, procurement values documentation and supply
It is advisable to request a COA and assay methods first, then run a small-sample validation to confirm it fits your system before bulk purchase.

figure3. Streptokinase and urokinase selection and application workflow
6. Custom Tool-Enzyme Development at MATWINGS MALL
6.1 Why Such Enzymes Benefit from Customization
Research in thrombolysis, fibrinolysis, and protease work often faces complex systems that standard commercial enzymes cannot cover: a specific expression host, a controlled active configuration such as the single- to two-chain ratio, removal of a hard-to-remove impurity, or an engineered variant with lower immunogenicity. Standard catalog products usually ship to a general specification.
6.2 Custom Capability and Path to Deployment
MATWINGS MALL offers custom tool-enzyme development services. Around this topic's protease and plasminogen-activator directions, it can help with expression-system selection, sequence and codon optimization, fermentation or culture process, and purification and quality-control design, advancing step by step to bulk supply as the project requires. The specific scope and quality targets follow public platform information and mutual evaluation.
If you have a research or process need in protease or thrombolysis, you can contact the MATWINGS MALL custom tool-enzyme development page or expert center for tailored expression, purification, and QC recommendations.
7. FAQ
7.1 What Is the Difference Between Streptokinase and Urokinase?
Both are plasminogen activators that dissolve clots. Streptokinase comes from streptococci, is inexpensive, but is immunogenic and may cause allergy; urokinase is human-derived, less immunogenic, and repeatably dosed, though costlier. The choice weighs efficacy, safety, and cost.
7.2 Why Does Streptokinase Dissolve Blood Clots?
Streptokinase binds human plasminogen to form an active complex, converting plasminogen into plasmin, which degrades the fibrin in a clot and dissolves it. Streptokinase itself is not a protease but a plasminogen activator.
7.3 Why Does Urokinase Dissolve Blood Clots?
Urokinase is a plasminogen activator that converts plasminogen into the active protease plasmin, and plasmin degrades the fibrin mesh in a clot, dissolving it. It is a human serine protease known as uPA.
7.4 What Are the Main Risks of Both?
The main risk is bleeding. Both are non-fibrin-selective, raising systemic, especially intracranial, bleeding risk; in addition, streptokinase can cause allergy. Bleeding risk and contraindications must be assessed before use.
7.5 How Should I Choose for Research or Process Work?
Choose by purpose: for one-time, budget-sensitive use, choose streptokinase; for repeat dosing or catheter recanalization where immunogenicity matters, choose urokinase. In either case, check specific activity, purity, endotoxin, and batch stability, and validate a small sample first.
